Neuro-immunotherapy of Untreatable Metastatic Solid Tumors with Subcutaneous Low-dose Interleukin-2, Melatonin and Naltrexone: Modulation
of Interleukin-2-induced Anti-tumor Immunity by Blocking the Opioid System, Lissoni, Malugani, Malysheva, et al., Neuroendocrinol.
Lett. 2002; 23 (4): 341-344.
A New Neuro-immunotherapeutic Strategy of Subcutaneous Low-dose Interleukin-2 plus the Long-acting
Opioid Antagonist Naltrexone in Metastatic Cancer Patients Progressing on Interleukin-2 Alone, Lissoni, Malugani, Bordin, et al.,Neuroendocrinol. Lett. 2002; 23 (3): 255-258.
Opioid Growth Factor Regulates the Cell Cycle of Human Neoplasias, Zagon, Roesener,
Verderame, et al., Int. J. Oncol. 2000; 17 (5): 1053-1061.
Reversal of Signs and Symptoms of a B-cell Lymphoma in a Patient Using
only Low-dose Naltrexone, Integr. Cancer Ther. 2007; 6 (3): 293-296.
The Long-term Survival of a Patient with Pancreatic Cancer
with Metastases to the Liver after Treatment with the Intravenous Alpha-Lipoic Acid/Low-dose Naltrexone Protocol, Berkson, Rubin &
Berkson, Integr. Cancer Ther. 2006; 5 (1): 83-89.